Malaria Vaccines Show Promise Amid Supply Shortages and Funding Challenges in Africa

Recent developments in malaria control highlight ongoing challenges and progress with vaccines like RTS,S and R21, amid supply shortages and new research insights. Tropical Health Matters reports that since 2019, Kenya's pilot Malaria Vaccine Implementation Programme has significantly reduced death rates and hospitalizations in children under 2, thanks to the RTS,S vaccine developed by GlaxoSmithKline over 35 years, with support from WHO, GAVI, and PATH. Similar gains have been seen in Ghana and Malawi through WHO-led rollouts integrated with routine immunizations and malaria interventions.

Demand for these vaccines far exceeds supply, according to UNICEF, raising concerns over production, supply chains, pricing, and integration into health systems. GAVI notes partners are providing technical assistance for country readiness, while parental hesitancy persists; a study in Ghana found 34.5% of parents reluctant to give children the R21/Matrix-M vaccine despite its high safety and efficacy, particularly among those skipping routine shots.

Funding cuts, including U.S. PMI suspension, threaten progress, with Roll Back Malaria Partnership estimating 12.5-17.9 million more cases and 71,000-166,000 deaths this year, plus supply gaps in diagnostic tests across endemic nations. WHO and allies are stepping in with extra support.

Scientific advances offer hope. An eLife preprint identifies PfGBP-130 as a key ligand on Plasmodium falciparum-infected red blood cells that activates NK cells via LFA-1, boosting their cytotoxic response against parasites and revealing potential host-directed therapies. Rotary International highlights infrastructure from Mosquirix (RTS,S) and R21 easing paths for newcomers, like Australia's PlasProtecT whole-parasite vaccine entering Phase 1 trials this year after strong preclinical results against strains.

In Nigeria, Bauchi State launched malaria vaccination alongside polio drives for 2 million children under 5, per Tribune Online NG, underscoring grassroots momentum. With global deaths exceeding 600,000 annually for three years, experts like Prof. Carlton Hay emphasize research and innovation, including the scalable, affordable R21 from Oxford and Serum Institute of India, offering up to 80% protection with three doses plus booster. These efforts signal a multifaceted push against a resilient parasite.

This content was created in partnership and with the help of Artificial Intelligence AI